C
Originally published by Capital Businessbusiness
March 18, 2026
2h ago
India’s cheap weight-loss drugs could reshape global obesity fight
On Friday the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country. Kenya breaking news | Kenya news today |..
✨ Key Highlights
India is poised to significantly impact the global fight against obesity as the patent expiration of semaglutide, the molecule behind popular weight-loss drugs like Wegovy and Ozempic, allows domestic companies to produce cheaper generic versions.
- Generic versions are expected to cut monthly treatment costs from approximately $95-$173 to an estimated $36-$54, potentially increasing access by more than 50%.
- Key Indian pharmaceutical companies like Cipla, Sun Pharma, and Dr Reddy’s Laboratories are preparing to launch multiple generic brands.
- This development leverages India's established strength as the "pharmacy of the world" in generic medicine manufacturing, with potential export markets in the US alone scaling to $10 billion.
Continue Reading
Read the complete article from Capital Business
Advertisement
Related News
Advertisement